Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. - Wikidata - wikimedia - TriplyDB

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

http://www.wikidata.org/entity/Q44924769

about

Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes Antiretroviral medication: an emerging category of prescription drug misuse A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice Endogenous opiates and behavior: 2006 Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs.Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis.Interactions between alcohol and the HIV entry inhibitor Maraviroc.Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment Management of HIV infection in patients with substance use problems Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells.Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?Buprenorphine implant for opioid addiction Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.Gender differences in pharmacokinetics of maintenance dosed buprenorphine.Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy Clinical care of the HIV-infected drug user Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Narrative review: buprenorphine for opioid-dependent patients in office practice.Drug interactions in the management of HIV infection: an update.Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.Lack of clinically significant drug interactions between nevirapine and buprenorphine.Treatment of opioid-dependent pregnant women: clinical and research issues.Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.Methadone, buprenorphine, and street drug interactions with antiretroviral medications Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Buprenorphine for cancer pain: is it ready for prime time?Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products

P2860

Q24629014-067A2A31-C8CA-4288-BBC1-FFD82F3BD9F5 Q24631289-E72C0DCB-2DDE-471F-97A3-363556A4B259 Q24649164-A4894D2B-A769-486A-ACC0-C62EF1AF7AC4 Q26852974-6937EFCE-829E-4A72-B1C5-EAE4317B7B62 Q27692040-DE71E41A-DA57-48B9-BA7F-565EE789B7A2 Q28752585-27902590-9358-4168-B842-C29407F26BED Q33640426-C9D607DB-AEEE-4896-9F47-7D609AAB2E84 Q33842214-FBC43139-63D7-4576-8B76-47D0D8CB95B7 Q33909050-5473A1B6-723F-4966-B710-EAEC5C200186 Q33977281-5179EE1D-D7D8-4AA5-8DEC-EA85056E61C6 Q34113784-91F390AE-3F3D-492A-89F6-0BDFB10D1A6E Q34359979-9177F766-085A-4822-8782-29EBB06CA26B Q34403692-F08D9059-232F-4DCA-B98F-58FAA68628A5 Q34820000-54994B59-4D68-45D9-9EEF-B2266F39776E Q34851665-2BD558CF-D49E-4663-A7AF-340FCD1CD72A Q34965527-19A8DADE-7EBD-4E7B-B50E-E819866BFBED Q35184385-AA32960D-BE23-402E-AA13-467CE110719C Q35738851-159353A8-2835-4D4E-88D4-A9440878EECB Q35738878-F037E660-A63E-4251-9A8F-4CF1F7BF3296 Q35738885-C78A9809-9854-4011-92DA-505808DDB7A6 Q35906594-F431B10E-9274-47F2-BCD6-57CB5FF72CEE Q36086391-7BF82A9D-3EBB-4C7C-99BE-C24C37A7141E Q36248580-E6219E1F-023F-42EC-B50A-3609367AC1AF Q36655057-78A41143-E84A-4798-BF57-2C77CA3BCDA9 Q36959052-1D9CE468-AD2E-4B2C-9B0E-12BA04386C63 Q37000733-F5675ADD-C782-444F-89A8-3FE7828A29C5 Q37045335-9AB83E41-14C4-4306-BCD7-F6AC7F3A86CF Q37045349-6E416738-51E3-4DFB-B236-12312F22B8A7 Q37076673-248CFC1F-6FF7-4F93-A0F5-397B13C99181 Q37125615-977AB9C0-6263-4593-B65B-723B455AC5B7 Q37470350-81F75F3F-1E6E-4EB3-8BE6-9151037AC2B2 Q37699049-54074E5C-3ABA-4C5D-9AD7-555C22490BCB Q37705253-57F9E7E1-A2CC-4AFC-B052-CAA57B4A9C9B Q37721776-FF2C33AC-D6D1-4A44-929E-E5D1A5C579B3 Q37763615-06F969CF-6EE3-41D2-B36D-869A6BA72B6D Q37830040-31148EE6-4787-438F-8BF4-E0D90D888461 Q37845854-3ED10123-6123-4D8F-80CA-45BACFA7FB2F Q38243938-8D171417-04CC-4BCB-88C7-085555D72628 Q38435908-A7FA019C-B140-4AFD-9857-9BE5CF4D18E5 Q38513275-840612A7-06FD-4C81-B7FB-DB91DB5FFDFA

P2860

Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

http://www.wikidata.org/entity/Q44924769

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@en

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@nl

type

label

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@en

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@nl

prefLabel

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@en

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@nl

P1433

Q44924769-DC7C99FE-BE9D-4356-81ED-C48D48295020

P1476

Q44924769-F89B8FA4-46CA-4EE2-96F8-0FA4FE0E0A51

P2093

Q44924769-1CD8C48B-C3E4-4265-862B-798CF53B2A31

Q44924769-2CC06879-47F1-4CFF-9B0A-77422B51FAFF

Q44924769-2EE020AB-A65E-49EC-B25E-8C5C0AA1F41C

Q44924769-36DAC2F1-5408-4249-B69F-D4A83041652A

Q44924769-4F1D9C2E-9978-4E02-BDEF-AB5034C7C876

Q44924769-644D5753-3297-4719-8F8B-627D85A657A6

Q44924769-73268F84-891B-49E5-9727-8B0A56D3B8B2

Q44924769-B508BE37-5F52-4DD1-A7AF-1C17ED5CF85B

Q44924769-B6236246-FB86-47F5-BA57-429B2B33AD56

Q44924769-F326F50F-42D8-47D5-AC64-85A0B323A3C7

P2860

Q44924769-1548380A-C15C-4E2F-B480-132527BF8622

Q44924769-205259A0-0033-4917-B5FB-644D128672BC

Q44924769-3CBDF1A9-E68E-4FBD-B795-9CB4D11EA6A6

Q44924769-480CD884-6D22-4A9F-A55E-FA09577C9FB0

Q44924769-4E91F192-27F5-4377-950F-EF576AA6AB8A

Q44924769-75EC10D1-0780-42D5-9C52-E96D527E579D

Q44924769-80816CE3-9C0E-4996-8857-124C358EE20D

Q44924769-89C255A4-9AB7-42E1-B1FE-0353DBBAE5FC

Q44924769-B55AADDE-4CC9-410C-93B2-717EB3E8B619

Q44924769-B702AE08-4561-435F-ADC4-8035242E5944

P304

Q44924769-F8A4A65D-3D53-485C-95C5-0C633FEC780E

P31

Q44924769-E923AE9A-F598-444A-8B89-FB0A3420C38A

P356

Q44924769-C0A26ABE-1627-494D-B24A-439D3B466B7F

P407

Q44924769-14071EF6-AB26-4134-A8A0-BDFC7226AA05

P478

Q44924769-FC8BFBB4-0226-4406-AB2A-E9360284516C

P577

Q44924769-02A0C5EB-F3A5-41E7-A652-91B29B083F15

P5875

Q44924769-E3D953AA-B661-4025-A785-8578CE6E563E

P698

Q44924769-2036ECBB-4CFD-435D-A3E3-BBEC71399F1F

P921

Q44924769-869AB454-AFE2-407B-BBA8-CC7800D4F527

P356

P1433

Clinical Infectious Diseases

P1476

Interactions between buprenorp ...... ors efavirenz and delavirdine.

@en

P2093

Abayomi Ogundele

http://www.w3.org/2001/XMLSchema#string

Anika Alvanzo

http://www.w3.org/2001/XMLSchema#string

David E Moody

http://www.w3.org/2001/XMLSchema#string

Elinore F McCance-Katz

http://www.w3.org/2001/XMLSchema#string

Gene D Morse

http://www.w3.org/2001/XMLSchema#string

Gerald Friedland

http://www.w3.org/2001/XMLSchema#string

Jennifer Baker

http://www.w3.org/2001/XMLSchema#string

Patricia Pade

http://www.w3.org/2001/XMLSchema#string

Patrick Smith

http://www.w3.org/2001/XMLSchema#string

Peter Jatlow

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.

Clinical pharmacology of buprenorphine: ceiling effects at high doses.

Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.

Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects.

Office-based buprenorphine treatment for opioid-dependent patients.

Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents.

Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation.

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.

Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

P304

S224-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/508187

http://www.w3.org/2001/XMLSchema#string

P407

P478

43 Suppl 4

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6689121

http://www.w3.org/2001/XMLSchema#string

P698

17109309

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug